This second briefing paper is provided through the RMOC system. It forms the May edition of an expected monthly series of briefings on best value biological medicines. The briefing summarises: advice on the next steps for commissioners and providers; practical advice in the context of homecare services; and progress to date in planning for the patent expiry of the originator adalimumab product Humira® in October 2018. In addition, a clinical briefing sheet is provided as well as an adalimumab homecare patient record form.
Assistant Head (Medicines Optimisation), Specialist Pharmacy Service